Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
91-105 of 437
Communicating Pathologic Response Results in Resectable NSCLC
Project Oncology®Communicating Pathologic Response Results in Resectable NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Alexander Spira, MD, PhD, FACP
Robert Merritt, MD
Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Project Oncology®Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Deepa Rangachari, MD
Managing Immune-Related Adverse Events in Metastatic NSCLC
Project Oncology®Managing Immune-Related Adverse Events in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Paul Bunn, MD
Managing High-Risk Subgroups in Metastatic NSCLC
Project Oncology®Managing High-Risk Subgroups in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Melina Marmarelis, MD
Deepa Rangachari, MD
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Project Oncology®Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Brian P. McDonough, MD, FAAFP
Stacey Cohen, MD
Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Project Oncology®Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Charles Turck, PharmD, BCPS, BCCCP
Stephanie Gregory, CNP
- advertisement
Real-World Strategies for Complex cGVHD Treatment Decisions
Project Oncology®Real-World Strategies for Complex cGVHD Treatment Decisions
Brian P. McDonough, MD, FAAFP
Doris M. Ponce, MD, MS
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Project Oncology®Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Charles Turck, PharmD, BCPS, BCCCP
Laura Alder, MD
Christine Bestvina, MD
Emerging Therapeutic Strategies in Metastatic NSCLC
Project Oncology®Emerging Therapeutic Strategies in Metastatic NSCLC
Brian P. McDonough, MD, FAAFP
Urs Weber, MD
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Project Oncology®Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Alexandria May, PharmD, BCPS
Adam Brufsky, MD, PhD
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Project Oncology®Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Charles Turck, PharmD, BCPS, BCCCP
Daniel Geynisman, MD
Jonathan Henderson, MD
Addressing Barriers to CAR T Referral in R/R LBCL
Project Oncology®Addressing Barriers to CAR T Referral in R/R LBCL
Steve Jackson, PharmD
Matthew J. Matasar, MD
Tycel Phillips, MD
- advertisement
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Project Oncology®Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Steve Jackson, PharmD
Raghava Reddy Induru, MD
Optimizing Multidisciplinary Care in Perioperative NSCLC
Project Oncology®Optimizing Multidisciplinary Care in Perioperative NSCLC
Steve Jackson, PharmD
David Tom Cooke, MD, FACS
Joshua Reuss, MD
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Project Oncology®Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Brian P. McDonough, MD, FAAFP
Bilal Siddiqui, MD